Skip to main content
. Author manuscript; available in PMC: 2022 Aug 28.
Published in final edited form as: Cancer Lett. 2021 May 24;514:79–89. doi: 10.1016/j.canlet.2021.05.011

Figure 9. The association between TP53 mutational status/copy number loss and RHAMM/HMMR expression levels in TCGA pancreatic cancer dataset.

Figure 9.

(A) Upregulation of RHAMM/HMMR expression in the TCGA pancreatic cancer patients with TP53 mutations. WT: wild type (n = 53); MU: mutation (n = 66). (B) Upregulation of RHAMM/HMMR expression in the patients with copy number loss (CN = 1, n = 49) compared to autosomal copy number (CN = 2, n = 59). (C) Combination of TP53 mutations and high RHAMM/HMMR expression predicted worse outcome. (D) Combination of TP53 copy number loss (CN = 1) and high RHAMM/HMMR expression predicted worse outcome. High (H) and low (L) was based on the 75 quartile RHAMM/HMMR expression value. P values from log-rank test were shown in C and D.